Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 8 von Hippel-Lindau Disease 3 Pheochromocytoma 2 Paraganglioma 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Ovarian Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neoplasm Metastasis 1 Metastatic Castration-Resistant Prostate Cancer 1 Kidney Neoplasms 1 Hemangioblastoma 1 Endometrial Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma 1 Breast Neoplasms 1 Adenoma, Islet Cell 1

Interventions

Cisplatin 12 pembrolizumab 11 Magnetic Resonance Spectroscopy 11 Specimen Handling 10 Paclitaxel 6 Platinum 5 Cyclophosphamide 5 1,2-diaminocyclohexaneplatinum II citrate 5 fludarabine 4 durvalumab 4 cemiplimab 4 Radiotherapy, Intensity-Modulated 4 Radiotherapy 3 Pemetrexed 3 Oxaliplatin 3 Nivolumab 3 Fluorouracil 3 Cetuximab 3 Carboplatin 3 Biopsy 3 poly ICLC 2 fludarabine phosphate 2 cabozantinib 2 atezolizumab 2 Radiation 2 Ipilimumab 2 Interviews as Topic 2 Heavy Ion Radiotherapy 2 Gemcitabine 2 Drug Therapy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Carcinoma × belzutifan × Clear all

NCT07227402 2026-06-04

LITESPARK-033

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡